223 related articles for article (PubMed ID: 38611096)
21. Adrenomedullin induces cisplatin chemoresistance in ovarian cancer through reprogramming of glucose metabolism.
Dou L; Lu E; Tian D; Li F; Deng L; Zhang Y
J Transl Int Med; 2023 Jul; 11(2):169-177. PubMed ID: 37408575
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
[TBL] [Abstract][Full Text] [Related]
23. Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism.
Samec M; Liskova A; Koklesova L; Samuel SM; Zhai K; Buhrmann C; Varghese E; Abotaleb M; Qaradakhi T; Zulli A; Kello M; Mojzis J; Zubor P; Kwon TK; Shakibaei M; Büsselberg D; Sarria GR; Golubnitschaja O; Kubatka P
EPMA J; 2020 Sep; 11(3):377-398. PubMed ID: 32843908
[TBL] [Abstract][Full Text] [Related]
24. Lactate and Lactate Transporters as Key Players in the Maintenance of the Warburg Effect.
Pereira-Nunes A; Afonso J; Granja S; Baltazar F
Adv Exp Med Biol; 2020; 1219():51-74. PubMed ID: 32130693
[TBL] [Abstract][Full Text] [Related]
25. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.
Hagiwara M; Kikuchi E; Tanaka N; Kosaka T; Mikami S; Saya H; Oya M
BMC Cancer; 2018 Jan; 18(1):113. PubMed ID: 29385995
[TBL] [Abstract][Full Text] [Related]
26. Malignancy Grade-Dependent Mapping of Metabolic Landscapes in Human Urothelial Bladder Cancer: Identification of Novel, Diagnostic, and Druggable Biomarkers.
Iliou A; Panagiotakis A; Giannopoulou AF; Benaki D; Kosmopoulou M; Velentzas AD; Tsitsilonis OE; Papassideri IS; Voutsinas GE; Konstantakou EG; Gikas E; Mikros E; Stravopodis DJ
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32164285
[TBL] [Abstract][Full Text] [Related]
27. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
[TBL] [Abstract][Full Text] [Related]
28. Metabolic phenotype of bladder cancer.
Massari F; Ciccarese C; Santoni M; Iacovelli R; Mazzucchelli R; Piva F; Scarpelli M; Berardi R; Tortora G; Lopez-Beltran A; Cheng L; Montironi R
Cancer Treat Rev; 2016 Apr; 45():46-57. PubMed ID: 26975021
[TBL] [Abstract][Full Text] [Related]
29. Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells.
Dong Q; Zhou C; Ren H; Zhang Z; Cheng F; Xiong Z; Chen C; Yang J; Gao J; Zhang Y; Xu L; Fang J; Cao Y; Wei H; Wu Z
Cell Commun Signal; 2020 Oct; 18(1):167. PubMed ID: 33097055
[TBL] [Abstract][Full Text] [Related]
30. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
Wen JF; Jiang YQ; Li C; Dai XK; Wu T; Yin WZ
Cancer Biomark; 2020; 28(2):231-246. PubMed ID: 32508321
[TBL] [Abstract][Full Text] [Related]
31. Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism.
Yeon A; You S; Kim M; Gupta A; Park MH; Weisenberger DJ; Liang G; Kim J
Theranostics; 2018; 8(16):4520-4534. PubMed ID: 30214636
[TBL] [Abstract][Full Text] [Related]
32. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
33. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance.
Afonso J; Santos LL; Miranda-Gonçalves V; Morais A; Amaro T; Longatto-Filho A; Baltazar F
Mol Carcinog; 2015 Nov; 54(11):1451-66. PubMed ID: 25263481
[TBL] [Abstract][Full Text] [Related]
34. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
Schlütermann D; Skowron MA; Berleth N; Böhler P; Deitersen J; Stuhldreier F; Wallot-Hieke N; Wu W; Peter C; Hoffmann MJ; Niegisch G; Stork B
Urol Oncol; 2018 Apr; 36(4):160.e1-160.e13. PubMed ID: 29276062
[TBL] [Abstract][Full Text] [Related]
35. Suppression of HAX-1 induced by miR-325 resensitizes bladder cancer cells to cisplatin-induced apoptosis.
Li R; Zheng JZ; Huang X
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9303-9314. PubMed ID: 33015771
[TBL] [Abstract][Full Text] [Related]
36. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
Shi ZD; Hao L; Han XX; Wu ZX; Pang K; Dong Y; Qin JX; Wang GY; Zhang XM; Xia T; Liang Q; Zhao Y; Li R; Zhang SQ; Zhang JH; Chen JG; Wang GC; Chen ZS; Han CH
Mol Cancer; 2022 Feb; 21(1):37. PubMed ID: 35130920
[TBL] [Abstract][Full Text] [Related]
37. Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway.
Sun Y; Chen Y; Xu M; Liu C; Shang H; Wang C
Biomed Res Int; 2020; 2020():9243681. PubMed ID: 32685545
[TBL] [Abstract][Full Text] [Related]
38. Coenzyme Q
Yang HL; Lin PY; Vadivalagan C; Lin YA; Lin KY; Hseu YC
Arch Toxicol; 2023 Apr; 97(4):1047-1068. PubMed ID: 36847822
[TBL] [Abstract][Full Text] [Related]
39. Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness.
Afonso J; Santos LL; Morais A; Amaro T; Longatto-Filho A; Baltazar F
Cell Cycle; 2016; 15(3):368-80. PubMed ID: 26636903
[TBL] [Abstract][Full Text] [Related]
40. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
